Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 323-336

  Ye, Lei ^a   Haider, Husnain Kh ^b   Esa, Wahidah Bte ^c   Su, LiPing ^a   Law, Peter K ^c,d   Zhang, Wei ^e   Lim, YeanTeng ^f   Poh, Kian Keong ^f   Sim, Eugene K W ^g,h  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c INSTITUTE OF MENTAL HEALTH   (Singapore)

^d Cell Transplants Pte Ltd   (Singapore)

^e HEALTH SCIENCES AUTHORITY   (Singapore)

^f NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^g MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^h Gleneagles JPMC Cardia Centre   (Brunei Darussalam)

Author keywords

Ischaemic limb disease; Liposome; Skeletal myoblast; VEGF165

Indexed keywords

LIPOSOME; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL; ARTICLE; BLOOD FLOW; CELL TRANSPLANTATION; CYTOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; ISCHEMIA; LIMB; METABOLISM; METHODOLOGY; MYOBLAST; PARTICLE SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; ULTRASTRUCTURE; VASCULARIZATION;

ANIMALS; CELL TRANSPLANTATION; EXTREMITIES; FEMALE; HUMANS; ISCHEMIA; LIPOSOMES; MYOBLASTS, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PARTICLE SIZE; RABBITS; REGIONAL BLOOD FLOW; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 77951950431     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00454.x     Document Type: Article

References (31)

1. Labs KH, Dormandy JA, Jaeger KA. Transatlantic conference on clinical trial guidelines in peripheral arterial disease: clinical trial methodology. Circulation. 1999, 100:e75-81.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg. 2000, 31:S1-296.
3. Weitz JI, Byrne J, Clagett GP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996, 94:3026-49.
4. Niagara MI, Haider Kh H, Ye lei. Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia. J Vasc Surg. 2004, 40:774-85.
5. Bobek V, Taltynov O, Pinterova D. Gene therapy of the ischemic lower limb-Therapeutic angiogenesis. Vasc Pharmacol. 2006, 44:395-405.
6. Yamada N, Li W, Ihaya A. Platelet-derived endothelial cell growth factor gene therapy for limb ischemia. J Vasc Surg. 2006, 44:1322-8.
7. Sica V, Williams-Ignarro S, Nigris F. Autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the diabetic mouse hindlimb. Cell Cycle. 2006, 5:2903-8.
8. Chang DS, Su H, Tang GL. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther. 2003, 7:44-51.
9. Smythe GM, Lai MC, Grounds MD. Adeno-associated virus-mediated vascular endothelial growth factor gene therapy in skeletal muscle before transplantation promotes revascularization of regenerating muscle. Tissue Eng. 2002, 8:879-91.
10. Isner JM, Baumgartner I, Rauh G. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998, 28:964-73.
11. Isner JM, Pieczek A, Schainfeld R. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996, 348:370-4.
12. Ye L, Haider Kh H, Esa WB. Non-viral vector based gene transfection of primary human skeletal myoblasts. Exp Bio Med. 2007, 232:1477-87.
13. Simberg D, Danino D, Talmon Y. Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J Biol Chem. 2001, 276:47453-9.
14. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999, 401:517-8.
15. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003, 10:935-40.
16. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 2000, 286:2244-45.
17. Sun JY, Anand-Jawa V, Chatterjee S. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 2003, 10:964-76.
18. Ye L, Haider Kh H, Tan RS. Transplantation of nanoparticle transfected skeletal myoblasts over-expressing vascular endothelial growth factor-165 for cardiac repair. Circulation. 2007, 116:I113-20.
19. Ye L, Haider HKh, Jiang S. Angiopoietin-1 induced myocardial neovascularization: a comparison between ex-vivo delivery using skeletal myobalsts vs direct viral vector injection. Eur J Heart Fail. 2007, 9:458-65.
20. Pu LQ, Sniderman AD, Brassard R. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 1993, 88:208-15.
21. Trivedi RA, Dickson G. Liposome-mediated gene transfer into normal and dystrophin-deficient mouse myoblasts. J Neurochem. 1995, 64:2230-8.
22. Ross PC, Hui SW. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther. 1999, 6:651-9.
23. Rejman J, Oberle V, Zuhorn IS. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004, 377:159-69.
24. Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996, 35:5616-23.
25. Brunner S, Sauer T, Carotta S. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther. 2000, 7:401-7.
26. Suzuki K, Murtuza B, Smolenski RT. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation. 2001, 104:I207-12.
27. Lee RJ, Springer ML, Blanco-Bose WE. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000, 102:898-901.
28. Tatsumi R, Hattori A, Ikeuchi Y. Release of hepatocyte growth factor from mechanically stretched skeletal muscle satellite cells and role of pH and nitric oxide. Mol Biol Cell. 2002, 13:2909-18.
29. Sejersen T, Betsholtz C, Sjolund M. Rat skeletal myoblasts and arterial smooth muscle cells express the gene for the A chain but not the gene for the B chain (c-sis) of platelet-derived growth factor (PDGF) and produce a PDGF-like protein. Proc Natl Acad Sci USA. 1986, 83:6844-8.
30. Kawamura AA, Horie T, Tsuda I. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs. 2006, 9:226-33.
31. Layman H, Spiga MG, Brooks T. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model. Biomaterials. 2007, 28:2646-54.